Why the study?
Does standard cardiac therapy improve late doxorubicin-induced cardiomyopathy?
Population
An adult patient who received 475 mg/sq m of doxorubicin hydrochloride and experienced a cardiotoxic…
Design
Case_report
Authors
Loading...
May support reversibility of late doxorubicin cardiomyopathy with standard therapy; single case leaves open generalizability.
Does standard cardiac therapy improve late doxorubicin-induced cardiomyopathy?
Late doxorubicin-induced cardiomyopathy may be reversible and responsive to standard cardiac therapy, challenging the previous belief that it is rapidly progressive and unresponsive.
Murray Cohen (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: